Kohno Keizo, Ohashi Emiko, Sano Osamu, Kusano Hajime, Kunikata Toshio, Arai Norie, Hanaya Toshiharu, Kawata Toshio, Nishimoto Tomoyuki, Fukuda Shigeharu
Core Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Functional Dye Division, Functional Dye Department, Hayashibara Co., Ltd, Okayama, Japan.
J Inflamm (Lond). 2015 Jan 20;12(1):2. doi: 10.1186/s12950-014-0045-0. eCollection 2015.
Adenosine is a potent endogenous anti-inflammatory and immunoregulatory molecule. Despite its promise, adenosine's extremely short half-life in blood limits its clinical application. Here, we examined adenosine N1-oxide (ANO), which is found in royal jelly. ANO is an oxidized product of adenosine at the N1 position of the adenine base moiety. We found that it is refractory to adenosine deaminase-mediated conversion to inosine. We further examined the anti-inflammatory activities of ANO in vitro and in vivo.
The effect of ANO on pro-inflammatory cytokine secretion was examined in mouse peritoneal macrophages and the human monocytic cell line THP-1, and compared with that of adenosine, synthetic adenosine receptor (AR)-selective agonists and dipotassium glycyrrhizate (GK2). The anti-inflammatory activity of ANO in vivo was examined in an LPS-induced endotoxin shock model in mice.
ANO inhibited secretion of inflammatory mediators at much lower concentrations than adenosine and GK2 when used with peritoneal macrophages and THP-1 cells that were stimulated by LPS plus IFN-γ. The potent anti-inflammatory activity of ANO could not be solely accounted for by its refractoriness to adenosine deaminase. ANO was superior to the synthetic A1 AR-selective agonist, 2-chloro-N(6)-cyclopentyladenosine (CCPA), A2A AR-selective agonist, 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamideadenosine hydrochloride (CGS21680), and A3 AR-selective agonist, N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA), in suppressing the secretion of a broad spectrum of pro-inflammatory cytokines by peritoneal macrophages. The capacities of ANO to inhibit pro-inflammatory cytokine production by THP-1 cells were comparable with those of CCPA and IB-MECA. Reflecting its potent anti-inflammatory effects in vitro, intravenous administration of ANO significantly reduced lethality of LPS-induced endotoxin shock. A significant increase in survival rate was also observed by oral administration of ANO. Mechanistic analysis suggested that the up-regulation of the anti-inflammatory transcription factor c-Fos was, at least in part, involved in the ANO-induced suppression of pro-inflammatory cytokine secretion.
Our data suggest that ANO, a naturally occurring molecule that is structurally close to adenosine but is functionally more potent, presents potential strategies for the treatment of inflammatory disorders.
腺苷是一种强效的内源性抗炎和免疫调节分子。尽管它前景广阔,但其在血液中的半衰期极短,限制了其临床应用。在此,我们研究了蜂王浆中含有的N1-氧化腺苷(ANO)。ANO是腺苷在腺嘌呤碱基部分N1位置的氧化产物。我们发现它对腺苷脱氨酶介导的转化为肌苷具有抗性。我们进一步研究了ANO在体外和体内的抗炎活性。
在小鼠腹腔巨噬细胞和人单核细胞系THP-1中检测ANO对促炎细胞因子分泌的影响,并与腺苷、合成腺苷受体(AR)选择性激动剂和甘草酸二钾(GK2)进行比较。在小鼠脂多糖诱导的内毒素休克模型中检测ANO在体内的抗炎活性。
当与经脂多糖加干扰素-γ刺激的腹腔巨噬细胞和THP-1细胞一起使用时,ANO抑制炎症介质分泌所需的浓度远低于腺苷和GK2。ANO的强效抗炎活性不能完全归因于其对腺苷脱氨酶的抗性。在抑制腹腔巨噬细胞分泌多种促炎细胞因子方面,ANO优于合成的A1 AR选择性激动剂2-氯-N(6)-环戊基腺苷(CCPA)、A2A AR选择性激动剂2-[对-(2-羧乙基)苯乙氨基]-5'-N-乙基甲酰胺腺苷盐酸盐(CGS21680)和A3 AR选择性激动剂N(6)-(3-碘苄基)腺苷-5'-N-甲基脲苷(IB-MECA)。ANO抑制THP-1细胞产生促炎细胞因子的能力与CCPA和IB-MECA相当。静脉注射ANO显著降低了脂多糖诱导的内毒素休克的致死率,这反映了其在体外的强效抗炎作用。口服ANO也观察到存活率显著提高。机制分析表明,抗炎转录因子c-Fos的上调至少部分参与了ANO诱导的促炎细胞因子分泌的抑制。
我们的数据表明,ANO是一种天然存在的分子,其结构与腺苷相近,但功能更强,为炎症性疾病提供了潜在的治疗策略。